Search

Your search keyword '"John D Turnidge"' showing total 287 results

Search Constraints

Start Over You searched for: Author "John D Turnidge" Remove constraint Author: "John D Turnidge"
287 results on '"John D Turnidge"'

Search Results

1. Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.

2. Minim typing--a rapid and low cost MLST based typing tool for Klebsiella pneumoniae.

3. Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia

5. Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers

6. Robotic Antimicrobial Susceptibility Platform (RASP): a next-generation approach to One Health surveillance of antimicrobial resistance

7. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

9. Etest ECVs/ECOFFs for detection of resistance in prevalent and three non-prevalent Candida spp. to triazoles and amphotericin B and Aspergillus spp. to caspofungin: Further assessment of modal variability

10. What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?

11. Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study

12. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

14. A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens

15. Taking AIM-(1) at carbapenem resistance in Pseudomonas aeruginosa

16. The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal

17. Inactivation, removal, and regrowth potential of opportunistic pathogens and antimicrobial resistance genes in recycled water systems

18. Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective

19. Efflux Pump-Driven Antibiotic and Biocide Cross-Resistance in Pseudomonas aeruginosa Isolated from Different Ecological Niches: A Case Study in the Development of Multidrug Resistance in Environmental Hotspots

20. Utilising sigmoid models to predict the spread of antimicrobial resistance at the country level

21. Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case study

22. Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper

23. Determination of norvancomycin epidemiological cut-off values (ECOFFs) for Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis

24. Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia

26. Recommendations for the control of carbapenemase-producing Enterobacteriaceae (CPE): A guide for acute care health facilities

27. Antimicrobial resistance in clinical Escherichia coli isolated from companion animals in Australia

28. Proposed method for estimating clinical cut-off (CO CL ) values: An attempt to address challenges encountered when setting clinical breakpoints for veterinary antimicrobial agents

29. Obituary: Johan Willem Mouton

30. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints

31. Estimating the utilisation of unregistered antimicrobials in Australia

32. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for

33. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme(AESOP) Annual Report 2015

34. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods

35. Polymyxin Susceptibility Testing and Breakpoint Setting

36. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds

37. Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patients

38. A plea from EUCAST for standardization of disc susceptibility testing antimicrobial codes

39. Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers

40. Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision

41. Posaconazole MIC distributions for Aspergillus fumigatus SC by four methods: Impact of Cyp51A mutations on estimation of epidemiological cutoff values

42. Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model

43. MIC-based dose adjustment: facts and fables

45. Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide

46. Antimicrobial susceptibility testing for bovine respiratory disease: Getting more from diagnostic results

47. The induction of Staphylococcus aureus biofilm formation or Small Colony Variants is a strain-specific response to host-generated chemical stresses

48. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia

49. Relative performance of antimicrobial susceptibility assays on clinical Escherichia coli isolates from animals

50. Assessing the public acceptability of proposed policy interventions to reduce the misuse of antibiotics in Australia: A report on two community juries

Catalog

Books, media, physical & digital resources